Clinical Trial Update: The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating the immunological effects of vemurafenib plus cobimetinib in patients with melanoma has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• vemurafenib + cobimetinib

Snippet

Sponsor: Georgetown University | Conditions: Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2018-11-07